Long-term study of K-877

Trial Profile

Long-term study of K-877

Phase of Trial: Phase III

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Pemafibrate (Primary)
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Kowa
  • Most Recent Events

    • 03 Jan 2018 Primary endpoint (Percentage change in fasting serum TG level from the baseline at the final evaluation over 24 weeks) has been met, according to results published in the Diabetes Care.
    • 03 Jan 2018 Results assessing the long-term efficacy and safety of pemafibrate treatment for over 24 weeks in patients with type 2 diabetes comorbid with hypertriglyceridemia, were published in the Diabetes Care.
    • 06 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top